Aleglitazar

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Aleglitazar
Aleglitazar.svg
Names
IUPAC name
(2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-benzothiophenyl]propanoic acid
Other names
Ro-0728804, R-1439
Identifiers
475479-34-6 N
ChEMBL ChEMBL519504 YesY
ChemSpider 8450255 YesY
DrugBank DB08483 YesY
Jmol-3D images Image
Image
KEGG D08845 YesY
PubChem 10274777
Properties
C24H23NO5S
Molar mass 437.51 g·mol−1
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N verify (what isYesY/N?)
Infobox references

Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is no longer in phase III clinical trials.[2]

References[edit]

  1. ^ "Statement on a nonproprietary name adopted by the USAN Council: Aleglitazar" (PDF). United States Adopted Names. American Medical Association. Retrieved 2008-08-17. 
  2. ^ "Roche halts diabetes drug trial in blow to pipeline". Roche. Retrieved 2013-07-10.